Li Xin, Han Zhiyu, Cheng Zhigang, Yu Jie, Yu Xiaoling, Liang Ping
a Department of Interventional Ultrasound , Chinese PLA General Hospital , Beijing , China and.
b Departent of Oncology , Dengzhou Renai Hospital , Henan , China.
Int J Hyperthermia. 2015;31(7):758-63. doi: 10.3109/02656736.2015.1068958. Epub 2015 Sep 22.
The aim of this study was to elucidate the clinical significance of preoperative Platelet-to-lymphocyte ratio (PLR) in recurrent hepatocellular carcinoma (RHCC) patients after thermal ablation.
We retrospectively reviewed 414 patients with RHCC treated with ultrasound-guided thermal ablation percutaneously between January 2010 and March 2014. The correlation of recurrence-free survival (RFS) with 15 clinical parameters was analysed by Cox multivariate proportional hazard model analysis. The best cut-off value of preoperative PLR was determined with time-dependent receiver operating characteristic (ROC) curve analysis. The value of PLR in predicting recurrence was analysed by Kaplan-Meier.
Multivariate Cox proportional hazard model analysis showed that tumour differentiation, prothrombin time (PT), absolute lymphocyte count (ALC) and PLR were risk factors for recurrence in RHCC patients. PLR ≥ 87.87 was considered for evaluation (AUROC = 0.667; P < 0.05), and 166 of 414 patients (40.1%) had PLR of more than 87.87. During the follow-up period (12-52 months), the 1- and 3-year recurrence rates were 39.9% and 54.8% in the low PLR group, which were significantly better than those in the high PLR group (56.0% and 79.5%) (P < 0.05). Kaplan-Meier analysis demonstrated that the RFS in the low PLR group was 45.2% which was significantly higher than that of the high PLR group (20.5%) (X2 = 24.019, P < 0.05). This result suggested that preoperative PLR is a predictor for recurrence followed thermal ablation in RHCC patients, and patients with PLR ≥ 87.87 indicated higher RFS, which may improve the clinical management of RHCC patients. Further studies are warranted to validated this finding and test its clinical applicability in RHCC.
本研究旨在阐明术前血小板与淋巴细胞比值(PLR)在热消融术后复发性肝细胞癌(RHCC)患者中的临床意义。
我们回顾性分析了2010年1月至2014年3月期间接受超声引导下经皮热消融治疗的414例RHCC患者。采用Cox多因素比例风险模型分析无复发生存期(RFS)与15项临床参数的相关性。通过时间依赖性受试者操作特征(ROC)曲线分析确定术前PLR的最佳截断值。采用Kaplan-Meier法分析PLR在预测复发中的价值。
多因素Cox比例风险模型分析显示,肿瘤分化程度、凝血酶原时间(PT)、绝对淋巴细胞计数(ALC)和PLR是RHCC患者复发的危险因素。PLR≥87.87被视为评估指标(曲线下面积=0.667;P<0.05),414例患者中有166例(40.1%)PLR超过87.87。在随访期(12 - 52个月)内,低PLR组的1年和3年复发率分别为39.9%和54.8%,显著低于高PLR组(56.0%和79.5%)(P<0.05)。Kaplan-Meier分析表明,低PLR组的无复发生存率为45.2%,显著高于高PLR组(20.5%)(X2 = 24.019,P<0.05)。这一结果表明,术前PLR是RHCC患者热消融术后复发的预测指标,PLR≥87.87的患者无复发生存率较高,这可能改善RHCC患者的临床管理。有必要进一步研究以验证这一发现并测试其在RHCC中的临床适用性。